Skip to content

An exploratory randomized controlled study of qianma Zhisou granule in the treatment of cough after infection

An exploratory randomized controlled study of qianma Zhisou granule in the treatment of cough after infection

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006030
Enrollment
Unknown
Registered
2022-05-23
Start date
2022-05-25
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cough after infection

Interventions

control group:Qianma Zhisou granule placebo
Treatment group:Qianma Zhisou granule

Sponsors

The First Affiliated Hospital of Henan University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: ? It is consistent with the diagnosis of cough after infection by traditional Chinese and Western medicine; ? Course of disease = 3 weeks and < 8 weeks; ? Those aged = 18 and = 60; ? The subjects were informed and voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: ? Allergic to known traditional Chinese medicine ingredients; ? Patients with unstable angina pectoris, acute myocardial infarction, resting pulmonary artery pressure > 45mmhg, cardiac function grade 2 and above; ? Combined with some chronic diseases, such as chronic obstructive pulmonary disease, bronchial asthma, cough variant asthma, reflux esophagitis, chronic pharyngitis, etcIrritable cough; ? Severe liver and kidney disease (severe liver disease refers to liver cirrhosis, portal hypertension and variceal bleeding. Severe kidney disease includes dialysis and kidney transplantation) ? Pregnant or preparing pregnant women, lactating women; ? Those who have participated in clinical trials of other drugs in recent 1 month; ? Patients with purulent sputum or suppurative tonsillitis; ? Patients with dementia and various mental diseases; ? Those who are participating in clinical trials of other interventions.

Design outcomes

Primary

MeasureTime frame
Cough symptom score;

Secondary

MeasureTime frame
Quality of life evaluation of cough;Visual analogue scale (VAS);TCM syndrome score;Clinical effective rate;Cough relief and disappearance time;

Countries

China

Contacts

Public ContactYang Jianya

The First Affiliated Hospital of Henan University of traditional Chinese Medicine

yangjianya2011@126.com15138477318

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026